Sphingosine (d18:1(14Z)) is an atypical sphingolipid that has a cis double bond at the 14-15 position. Sphingosine is a negative regulator of cell proliferation and can promote apoptosis.

LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research.

5-C-phenethyl-DNJ (hydrochloride) is an orally active acid α-glucosidase (GAA) activator. 5-C-phenethyl-DNJ (hydrochloride) can increase GAA activity in various tissues, particularly in the diaphragm. 5-C-phenethyl-DNJ (hydrochloride) can be used for the research of metabolic disease, such as Pompe disease.

Mc-Lys(PEG12)-Cap-Ala-Ala-PABC is a linker of MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan.

MDL 43291 is a competitive leukotriene (LT) receptor antagonist. MDL 43291 antagonize LTD4 and LTE4 with pA2 of 6.7. MDL 43291 does not antagonize histamine, carbachol or substance P. MDL 43291 can be used for the researches of inflammation and immunology, such as asthma.

SDNUM04 is a C-X-C chemokine receptor 4 (CXCR4) ligand and can be used as a tracer in tumor-targeting studies.

OncoACP3 TFA (Compound s43) is a high affinity ligand for prostatic acid phosphatase (ACP3). OncoACP3 TFA, radiolabelled with Lu-177, selectively accumulates in enzyme-expressing tumors and shows a potent anti-tumor activity with excellent tumor-selective payload deposition in HT1080.hACP3 and PC3.hACP3 tumor-bearing mice model. OncoACP3 TFA can be used for prostate cancer research.

OncoACP3 (Compound s43) is a high affinity ligand for prostatic acid phosphatase (ACP3). OncoACP3, radiolabelled with Lu-177, selectively accumulates in enzyme-expressing tumors and shows a potent anti-tumor activity with excellent tumor-selective payload deposition in HT1080.hACP3 and PC3.hACP3 tumor-bearing mice model. OncoACP3 can be used for prostate cancer research.

MC-GGFG-NH-CH2-O-propionic acid is a ADC linker that can be used in the synthesis of LM-D01.

XIAP ligand-Linker Conjugate 2 is an E3 ligase ligand-linker conjugate that incorporates the XIAP BIR2 ligand XB2M54175348) and linker. XIAP ligand-Linker Conjugate 2 can be used for synthesis of PROTAC GNE-1567.

UNC3133 (Compound 16) is a selective and orally active macrocyclic mer tyrosine kinase (MerTK) inhibitor with an IC50 of 8.1 nM. UNC3133 has certain selectivity towards the TAM family (Axl and Tyro3) (with a selectivity of approximately 7 times for Axl and about 10 times for Tyro3), and has similar inhibitory activity towards Flt3. UNC3133 exhibits anti-tumor and anti-infection activities.

12-Nitrolinoleate (12-Nitro-9-cis,12-cis-octadecadienoic acid) is an activator for peroxisome proliferator-activated receptor γ (PPARγ). 12-Nitrolinoleate is a nitrated form of linoleic acid. 12-Nitrolinoleate can be formed upon exposure to acidified nitrate and found in human red blood cells and plasma. 12-Nitrolinoleate can activate PPARγ-dependent gene expression in MCF-7 cells expressing PPARγ with an EC50 = 0.045 μM. 12-Nitrolinoleate is able to inhibit LPS-induced NF-κB transcription in RAW 264.7 cells. 12-Nitrolinoleate can inhibit IL-6, TNF-α and CCL2 induced by LPS.

MU1742-amide-C6-acid is a CK1δ/ε inhibitor. MU1742-amide-C6-acid can be used for synthesis of PROTAC AH081.

UNC10088 is a molecular glue targeting NSD2. UNC10088 mediates the formation of a stable ternary complex between SCFFBXO22 and the NSD2 PWWP1 domain. UNC10088 promotes ubiquitination of the SCFFBXO22-dependent NSD2 PWWP1 domain through reversible covalent bonding with the C326 region of FBXO22. UNC10088 could be used in cancer research.

DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer.

LCI765 is an orally active and selective PPARδ agonist, with an EC50 of 0.07 nM. LCI765 can be used for the research of diseases related to energy homeostasis such as metabolic syndrome.

NAA-004 is a novel azo compound formed by linking 5-aminosalicylic acid and 4-aminophenylacetic acid through an azo bond. NAA-004 has oral activity. NAA-004 can inhibit colon damage, intracavitary fluid accumulation, and MPO activity. NAA-004 can be used for research on colitis.

GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction.

SR 16234 (TAS-108) is a selective estrogen receptor modulator. SR 16234 is promising for research of pain symptoms associated with endometriosis.

PD 121981 is a angiotensin II receptor antagonist. PD 121981 can be used for the research of cardiovascular disease.

PDE4 ligand 2 is a CRBN E3 ligase ligand. PDE4 ligand 2 can be used to synthesize PROTAC such as PDE4 degrader-1. PDE4 ligand 2 can be studied in research for autoimmune and anti-inflammatory diseases.

KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia.

4-[(1E)-2-Nitroethenyl]benzoic acid is an E3 ligase ligand. 4-[(1E)-2-Nitroethenyl]benzoic acid can be used for synthesis of PROTAC BRD4 Degrader-38.

VUF26034 (Compound 12b) is a photoresponsive ligand for the human β2-adrenergic receptor (β2-AR.

MC-02479 is a novel cephalosporin. RWJ-54428 has good activity against most of the organisms tested, including methicillin-resistant staphylococci, E. faecalis, and penicillin-resistant pneumococci, and has moderate activity against E. faecium.

CGP 31608 is a semisynthetic penem derivative with antibacterial activity. CGP 31608 is resistant to many important beta-lactamases (including the mutationally derepressed chromosomal enzymes). CGP 31608 can be used for the research of infection.

S-1255 is an orally active and highly selective endothelin ETA receptor antagonist (Kd=0.39 nM). S-1255 blocks vasoconstriction and sustains hypotensive effects in hypertensive rats. S-1255 is promising for research of hypertension and cardiovascular disorders.

BC-1175 (CB-181963) is a novel cephalosporin and antibacterial agent. CB-181963 displays strong binding to altered PBP 2a. CB-181963 demonstrates marked efficacy against MRSA, Klebsiella pneumoniae, Streptococcus pneumoniae, and Escherichia coli.

BAYV-3522 is an orally effective cephalosporin. BAYV-3522 has antibacterial activity against Gram positive bacteria and some respiratory pathogens. BAYV-3522 can be used in the research of infectious conditions.

HMRZ-62 is an antibacterial agent. HMRZ-62 exhibits antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus faecalis (VRE).